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Abstract
Angiogenesis requires endothelial cell invasion and is crucial for wound healing and for tumor growth and metas-
tasis. Invasion of native collagen is mediated by the α5β1 integrin fibronectin receptor. Thus, α5β1 up-regulation on
the surfaces of endothelial cells may induce endothelial cell invasion to stimulate angiogenesis. We report that the
interaction of α5β1 with its PHSRN peptide ligand induces human microvascular endothelial cell invasion and that
PHSRN-induced endothelial cell invasion is regulated by α4β1 integrin and requires matrix metalloproteinase 1
(MMP-1). Moreover, our results show that exposure to PHSRN causes rapid, specific up-regulation of surface lev-
els of α5β1 integrin and significantly increases α5 integrin mRNA in microvascular endothelial cells. Consistent with
these results, α5 small interfering RNA abrogates PHSRN-induced surface α5 and MMP-1 up-regulation, as well as
blocking invasion induction. We also observed dose-dependent, PHSRN-induced α5β1 integrin up-regulation on en-
dothelial cells in vivo in Matrigel plugs. We further report that the PHSCN peptide, an α5β1-targeted invasion inhibitor,
blocks PHSRN-induced invasion, α5β1 up-regulation, α5 mRNA induction, and MMP-1 secretion in microvascular en-
dothelial cells and that systemic PHSCN administration prevents PHSRN-induced α5β1 up-regulation and angiogen-
esis in Matrigel plugs. These results demonstrate a critical role for α5β1 integrin and MMP-1 in mediating the
endothelial cell invasion and angiogenesis and suggest that PHSRN-induced α5 transcription and α5β1 up-regulation
may form an important feed-forward mechanism for stimulating angiogenesis.
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Introduction
Endothelial cells invade the extracellular matrix (ECM) early in angio-
genesis. The α5β1 and α4β1 integrin fibronectin receptors (FnRs) of
epithelial cells and fibroblasts have been shown to regulate invasion
in response to plasma fibronectin (pFn), a significant component of
all body fluids, and to pFn fragments made during wound healing
[1,2]. The α5β1 FnR specifically interacts with the PHSRN sequence
of pFn cell binding domain (CBD) fragments to stimulate invasion
[1,2], whereas the interaction of the α4β1 FnR with the connecting
segment LDV sequence functions to repress α5β1-mediated invasion
induction by intact pFn [3,4]. Because endothelial cells, fibroblasts,
and epithelial cells express both α4β1 and α5β1 [2,5], invasion induc-
tion requires separation of their binding sites by pFn fragmentation,
which occurs during clot dissolution [6].
The α5β1 FnR is upregulated in late-stage tumors during establish-
ment of the invasive phenotype [7], whereas α4β1 may be down-
regulated to cause constitutive, Fn-dependent invasion [1,3,4]. In
the absence of α4β1/LDV binding, the α5β1/PHSRN interaction
stimulates matrix metalloproteinase 1 (MMP-1)–dependent invasion
by both normal and metastatic carcinoma cells [1,3,4]. The impor-
tance of α5β1-mediated invasion in malignant progression is sug-
gested by results of both preclinical and clinical studies using an
α5β1 integrin–directed invasion inhibitor, the acetylated, amidated
PHSCN peptide (Ac-PHSCN-NH2 or ATN-161) to reduce tumori-
genesis, block metastasis, and prevent progression [1,8–11].
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The α5β1 fibronectin receptors of endothelial cells are important
therapeutic targets for promoting wound healing or for inhibiting
tumor growth and metastasis. α5β1 Expression on endothelial cells
is upregulated after the addition of angiogenic growth factors, especi-
ally during migration or angiogenic sprouting [12,13]. α5β1 Expres-
sion is also increased on vascular endothelial cells during choroidal
neovascularization [14], as well as on angiogenic sprouts in the cen-
tral nervous system [15]. Moreover, α5β1 integrin is uniformly over-
expressed on the luminal surfaces of tumor blood vessels, whereas there
is much reduced expression on quiescent endothelial cells [16,17].
These results suggest that invasion induction may specifically involve
surface α5β1 up-regulation, implying that in addition to stimulating
invasion, the PHSRN/α5β1 interaction may upregulate surface α5β1
integrin levels, perhaps in part by inducing the mRNA encoding the
α5 integrin subunit in microvascular endothelial cells.
On the basis of these observations, we formulated the hypothesis
that PHSRN induces α5β1-mediated invasion by endothelial cells to
promote angiogenesis. To test our hypothesis, we determined the
effects of acetylated, amidated PHSRN peptide (Ac-PHSRN-NH2)
treatment on invasive behavior, on surface levels of α5β1 FnR, and on
α5 mRNA levels in human microvascular endothelial cells (HMVECs).
We also assayed the effects of Ac-PHSCN-NH2, an α5β1-targeted
invasion inhibitor that prevented metastatic disease progression for
prolonged periods in preclinical models and phase 1 clinical trial
[1,8–11], on PHSRN-induced HMVEC invasion and on PHSRN-
induced angiogenesis in Matrigel plugs in nude mice. We found
that the PHSRN peptide induces MMP-1–dependent HMVEC
invasion, upregulates surface α5β1 integrin levels on HMVEC, in
part by inducing α5 integrin mRNA, and stimulates angiogene-
sis in vivo. Consistent with these results, we observed that both
PHSRN-induced α5β1 up-regulation and invasion were blocked in
α5-silenced HMVEC. We also report that the PHSCN peptide is
a potent inhibitor of PHSRN-induced invasion, α5β1 up-regulation,
and angiogenesis.
Materials and Methods
Cell Culture, Peptide Synthesis, Invasion and MMP-1 Activity
Assays, and Statistics
Dermal HMVECs (Clonetics, San Diego, CA) were cultured in
MCDB131 medium (Mediatech, Inc., Herndon, VA) as recom-
mended. pFn-Depleted FBS (Cambrex, Walkersville, MD) was pre-
pared as described [1,3]. Naturally serum-free sea urchin embryo
basement membranes (SU-ECM) were prepared for use as invasion
substrates, and in vitro invasion assays were performed as described [1–
4,18]. Acetylated, amidated PHSRN, HSPNR, LHGPEILDVPST
(LDV), PGVLSEHPTLID (scrambled LDV), GRGDSP (RGD),
VKNEED, PHSCN, and HSPNC peptides were synthesized as pre-
viously described [1–4]. In subsequent in vitro assays, serum-starved
HMVECs were treated with the following combinations of peptides:
1 μg of Ac-PHSRN-NH2 per 20,000 cells and/or equimolar con-
centrations of acetylated, amidated HSPNR, LDV, scrambled LDV,
PHSCN, or HSPNC peptides. P1D6 anti-α5β1, P1B5 anti-α3β1,
P4C2 anti-α4β1, COMY4A2 anti–MMP-1, CA-4001 anti–MMP-2, or
GE-213 anti–MMP-9 monoclonal antibody (mAb; Chemicon In-
ternational, Temecula, CA), the 120-kDa Fn CBD (Chemicon), or
isotype controls (Sigma-Aldrich, St. Louis, MO and eBioscience, San
Diego, CA) were prebound to cells for invasion assays as described
[1,3,4]. Adherent HMVECs were treated with peptides and MMP-1
activities determined as described [3,4]. MMP-1 activity was measured
using the human active MMP-1 fluorescent assay system (R&D Sys-
tems, Minneapolis, MN). The relative fluorescence units of each well
were determined with a SpectraMax MS plate reader (Molecular De-
vices, Sunnyvale, CA).
Plasma membranes, excluding organelles, were prepared from serum-
starved, peptide-treated HMVEC as described above, according to
[19,20]. Plasma membrane protein concentration was measured using
the DC protein assay (Bio-Rad, Hercules, CA). Anti-α5 mAb CD 49e
(BD Biosciences, San Jose, CA) was used to analyze α5 integrin ex-
pression by Western blot analysis. Anti-α4 mAb P4C2 (Chemicon)
was used to immunoprecipitate α4β1 from plasma membrane ex-
tracts, and anti-β1 mAb N29 (Chemicon) antibodies were used to
analyze α4β1 expression levels by Western blot analysis. Band densities
were quantitated with ImageJ, obtained at http://rsb.info.nih.gov/ij/.
P values were calculated with independent samples Student’s t test
statistical program SPSS 15.0 (SPSS, Inc., Chicago, IL).
Fluorescent Antibody Staining and Image Analysis of
Fluorescence Intensity
Cells were serum-starved overnight on eight-well Permanox Lab-Tek
Chamber slides before incubating with peptides as described above
and/or with 1 mg/ml actinomycin D (Sigma) in 10% FBS for 2 hours
at 37°C. Treated cells were rinsed, fixed, and blocked with normal goat
serum (Vector Laboratories, Burlingame, CA) as previously described
[21]. Treated cells were incubated overnight at 4°C in a mixture of
anti-integrin and anti–MMP-1 primary antibodies: P1D6 anti-α5β1
(mAb1969) or P4C2 anti-α4β1 (mAb 1955) diluted 1:500, and
rabbit anti–MMP-1 antiserum (Ab), diluted 1:400 (Chemicon), or
with rabbit anti-α5β1 Ab (AB1928) diluted 1:500 (Chemicon), in
5% normal goat serum in PBS and Triton overnight at 4°C. After
rinsing, cells were incubated in antirabbit and antimouse second-
ary antibodies, conjugated with Cy3 or FITC, respectively ( Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA). After rinsing,
slides were mounted and analyzed by confocal microscopy as pre-
viously described [21–23]. The relative fluorescence intensities of
α5β1 and MMP-1 staining were calculated by using Image-Pro Plus
software (Media Cybernetics, Inc., Silver Spring, MD). Exactly 20
isolated cells per treatment were selected randomly for analysis at
400-fold magnification by blindly choosing fields and analyzing all
isolated cells in each field selected. The mean values of signal inten-
sities were obtained from all chosen cells and then copied and pasted
into Microsoft Excel data sheets for further analysis. All data are
expressed as mean ± SD and evaluated with Student’s t test (SPSS,
Inc.). Significance was set at P < .05.
Real-time Reverse Transcription–Polymerase Chain Reaction
Confluent HMVECs were serum-starved and treated with peptides
as described above. Total RNAwas isolated using RNeasy Plus Mini Kit
(QIAGEN GmbH, Hilden, Germany). RNA integrity was assessed
with Agilent 2100 BioAnalyser (Agilent Technologies, Waldbronn,
Germany). One-step reverse transcription–polymerase chain reaction
(RT-PCR) was performed using the QIAGEN RT-PCR Kit (QIAGEN
Catalog number 204243), as directed. The integrin α5 primers used
and reaction conditions have been previously described [24,25]. Glyc-
eraldehyde 3-phosphate dehydrogenase primers were used as standards,
as previously described [26]. Data were collected using ABI PRISM
7900HT Sequence Detection System (Applied Biosystems, Foster City,
CA). Data analysis was performed with software SDS 2.2.1 (Applied
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Biosystems). Normalized expression was calculated using the compara-
tive threshold cycle (C t) method, and fold changes were derived from
the 2−ΔΔC t values for α5. α5 Expression levels were normalized to glyc-
eraldehyde 3-phosphate dehydrogenase as described [26]. P values were
calculated with Student’s t test statistical program SPSS 15.0 (SPSS, Inc.).
Integrin Subunit α5 Small Interfering RNA Treatments
The integrin subunit α5 small interfering RNA (siRNA), nonspecific
control siRNA [27,28], fluorescein-conjugated control siRNA, siRNA
transfection reagent, and siRNA transfection medium (catalog numbers
sc-29372, sc-37007, sc-36869, sc-29528, and sc-36868, respectively)
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA).Cells were seeded into six-well plates (2.5 × 105/well) inMCDB131
with 10% FBS 24 hours before transfection. Cells were transfected
using siRNA transfection reagent (Santa Cruz Biotechnology) accord-
ing to the manufacturer’s instructions. The final concentration of siRNA
in each well was 40 nM. At 72 hours after transfection, cells were har-
vested for invasion assays and fluorescent antibody staining. Fluorescein-
conjugated control siRNA was used to evaluate transfection efficiency.
Matrigel Plug Assays
Matrigel plug assays were performed in female nude mice (Harlan
Sprague Dawley, Inc., Indianapolis, IN) using protocols approved by
the University Committee on Use and Care of Animals, as previously
described [29–31]. Acetylated, amidated PHSRN (0.1, 0.5, or 2.5 mg)
or HSPNR (2.5 mg) peptides, or 400 μg of basic fibroblast growth
factor (bFGF; Fitzgerald Industries International, Inc., Concord, MA)
were added to 0.5 ml of Matrigel before subcutaneous injection.
Normal saline (NS), 0.1 ml containing 0.3 mg of acetylated, ami-
dated PHSCN or HSPNC, was injected into tail veins (days 0, 2, and
4). Each treatment group consisted of 10 plugs in five mice. Plugs
were removed (day 5), rinsed, and fixed as described [21–23]. Plugs
were cryoprotected with a sucrose series of 5% to 20% and frozen
in a mixture of Tissue-Tek OCT embedding medium [22]. Sections,
5 μm in thickness, were cut with a cryostat [21–23] from all plugs,
mounted on slides, and stained using the HT15-IKT kit (Sigma), as
directed. Mean numbers of microvessels were determined by counting
30 randomly chosen fields, at 400-fold magnification, on a microscope
(Axioplan; Carl Zeiss, Inc., Thornwood, NY).
Drabkin’s Assays for Hemoglobin
Matrigel plugs, each with 2.5 mg of PHSRN peptide or 2 million
MATLyLu rat prostate cancer cells [30], were implanted in nude
mice. Mice were treated with acetylated, amidated PHSCN or
HSPNC peptides for a total of 9 (MATLyLu) or 16 (PHSRN) days,
as described above. Plugs were removed and homogenized in 500 μl
of PBS, and exactly one third of each homogenized plug was pro-
cessed for hemoglobin levels, using Drabkin’s reagent (Sigma), as
directed. Each sample was assayed in duplicate, and results were nor-
malized to plug protein concentrations using Spectra Max Plus 384
(Molecular Devices, Sunnyvale, CA). Experiments were repeated,
and results were analyzed as described above.
Results
Endothelial Cell Invasion Regulated by α5β1 and α4β1 FnR
and Their Peptide Ligands
Submicromolar PHSRN peptide concentrations were evaluated for
HMVEC invasion induction using SU-ECM as invasion substrates in
medium containing 10% FBS [1–4,18]. The scrambled sequence
control, HSPNR, was also evaluated. In addition to the PHSRN se-
quence from the ninth type III module of the Fn CBD, α5β1 binds
the RGD and VKNEED sites reviewed in Altroff et al. [32]. Thus,
the GRGDSP and VKNEED peptides (Ac-GRGDSP-NH2 and Ac-
VKNEED-NH2) were also tested for HMVEC invasion induction.
A peptide containing the α4β1 binding site in the Fn type III con-
necting segment, the LDV peptide (Ac-LHGPEILDVPST-NH2)
and its scrambled sequence control, the scrambled LDV peptide
(Ac-PGVLSEHPTLID-NH2), were also combined with PHSRN at
equimolar concentrations [33,34] and tested for repression of PHSRN-
induced HMVEC invasion. As shown in Figure 1A, PHSRN stimulated
HMVEC invasion with a log-linear dose-response relationship at con-
centrations from 17 nM to 1.7 μM (10 ng/ml to 1 μg/ml), whereas
HSPNRhad no activity. Neither RGDnor VKNEED inducedHMVEC
invasion at concentrations of 1.7 μM (1.0 μg/ml). Figure 1A also shows
that the presence of equimolar LDV peptide prevented PHSRN-induced
HMVEC invasion, whereas an identical concentration of scrambled
LDV had no inhibitory effect. Also, neither LDV nor scrambled LDV
alone induced HMVEC invasion (data not shown). These results are
consistent with the invasive responses to PHSRN and HSPNR peptides
observed for mammary epithelial cells, normal keratinocytes, fibroblasts,
and prostate epithelial cells in the presence of FBS and for metastatic
human breast and prostate cancer cell lines on serum-free SU-ECM sub-
strates [1–4,11]. As expected from the presence of both the PHSRN and
LDV sequences on intact fibronectin, no invasion was observed in the
presence of 10% FBS without added PHSRN. Thus, the ability of
LDV to inhibit PHSRN-induced HMVEC invasion is consistent with
the expression of α5β1 and α4β1 FnR on endothelial cells [5,35].
The role of α5β1 integrin in PHSRN-induced HMVEC invasion
was confirmed through the use of the blocking anti-α5β1 mAb,
P1D6 [36]. The effects of increasing concentrations of P1D6 on
PHSRN-induced HMVEC invasion are shown in Figure 1B: the
mean invasion percentages of HMVECs pretreated with P1D6, be-
fore placement of SU-ECM in the presence of 1 μg/ml PHSRN pep-
tide in 10% FBS, are plotted. Invasion declined log-linearly, with
respect to increasing P1D6 concentrations, whereas prebinding the
cells to elevated concentrations of P1B5 blocking anti-α3 mAb had
no effect.
Because the α4β1/LDV interaction represses α5β1-mediated in-
vasion and MMP-1 induction [3,4,37], the effects of blocking anti-
α4β1 mAb (P4C2) on HMVEC invasion were assessed. Suspended
HMVECs were prebound to increasing concentrations of P4C2, then
placed on SU-ECM in 10% FBS. The effects of P4C2 on HMVEC
invasion are shown in Figure 1C : the mean invasion percentages of
P4C2-treated HMVECs, relative to a positive control (1.0 μg/ml
PHSRN), are plotted. Invasion increased log-linearly with increasing
P4C2 concentration, whereas the isotype control had no effect. The
dependence of P4C2 anti–α4β1-induced HMVEC invasion on pFn
was also confirmed. As shown in Figure 1D, no P4C2-induced inva-
sion occurred in 10% pFn-depleted FBS [1], whereas addition of pu-
rified pFn, at the concentration found in 10% FBS, seemed to fully
restore P4C2-induced invasion. These results illustrate the dependence
of invasion on fibronectin.
Role of MMP-1 in α5β1-Mediated HMVEC Invasion
The importance of MMP-1 collagenase in angiogenesis in vitro
[38] and the induction of MMP-1 secretion and MMP-1–dependent
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invasion by the PHSRN/α5β1 interaction [3,4] suggested that α5β1-
mediated HMVEC invasion specifically requires MMP-1 and that the
PHSRN peptide stimulates MMP-1 secretion. These hypotheses were
tested by prebinding HMVEC to increasing concentrations of block-
ing COMY4A2 anti–MMP-1 mAb, then inducing α5β1-mediated
HMVEC invasion in each of two ways: 1) treatment with 100 ng/ml
PHSRN peptide or 2) binding to 300 μg/ml P4C2 blocking anti-α4β1
mAb. Treated cells were placed on SU-ECM to quantitate invasion.
As shown in Figure 2A, prebinding HMVEC to increasing con-
centrations of COMY4A2 caused a log-linear decline in PHSRN-
induced invasion, whereas prebinding to blocking anti–MMP-2 or
anti–MMP-9 mAb had no effect. Similarly, as shown in Figure 2B,
increasing concentrations of COMY4A2 inhibited P4C2-induced
HMVEC invasion, whereas neither anti–MMP-2 nor anti–MMP-9
had discernable effects.
The effects of PHSRN and LDVon MMP-1 secretion were assessed
by spectrophotometric activity assays, performed on the concentrated
medium of adherent HMVEC, treated with combinations of PHSRN,
LDV, and scrambled LDV peptides. Exposure to PHSRN stimulated
the secretion of activated MMP-1, relative to untreated controls, as
shown in Figure 2C . Also, PHSRN-induced MMP-1 secretion was
prevented by the inclusion of equimolar LDV. In contrast, inclusion
Figure 1. Invasion regulation by PHSRN and LHGPEILDVPST. (A) PHSRN-induced invasion. X-axis, log peptide concentration (ng/ml);
Y-axis, mean invasion percentages relative to maximally stimulated controls (±SD). Black circles, 10 ng/ml to 1 μg/ml Ac-PHSRN-NH2.
Controls: black square, 1 μg/ml Ac-HSPNR-NH2; white circle, 1.0 μg/ml Ac-GRGDSP-NH2; gray circle, 1.0 μg/ml Ac-VKNEED-NH2; white
triangle, 100 ng/ml Ac-PHSRN-NH2 + 250 ng/ml Ac-LHGPEILDVPST-NH2; black triangle, 100 ng/ml Ac-PHSRN-NH2 + 250 ng/ml Ac-
PGVLSEHPTLID-NH2. (B) Inhibition of PHSRN-induced invasion by P1D6 anti-α5β1 mAb. X-axis, log Ab concentration (μg/ml); Y-axis,
mean invasion percentages, relative to 1 μg/ml Ac-PHSRN-NH2 without added P1D6 (±SD). Black circles, 10 to 300 μg/ml P1D6
mAb in the presence of 1.0 μg/ml Ac-PHSRN-NH2. White circles, 100 or 300 μg/ml P1B5 anti-α3β1 mAb in the presence of 1.0 μg/ml
Ac-PHSRN-NH2. (C) Invasion induction by anti-α4β1 blocking mAb P4C2. X-axis, log micrograms of P4C2 mAb per milliliter; Y-axis, mean
percentages of invaded cells relative to 1 μg/ml Ac-PHSRN-NH2 (±SD). Black circles, 0 to 300 μg/ml P4C2; white circle, 300 μg/ml
isotype control. (D) Dependence of P4C2-induced invasion on the presence of pFn. X-axis, media: a, 10% FBS with 300 μg/ml P4C2;
b, 10% pFn-depleted FBS with 300 μg/ml P4C2; c, 10% pFn-depleted FBS, with 10 μg/ml pFn and 300 μg/ml P4C2; d, 10% pFn-depleted
FBS, with 10 μg/ml pFn and 300 μg/ml isotype control Ab; e, 10% FBS, with 300 μg/ml isotype control. Y-axis, mean percentages of
invaded cells relative to 1 μg/ml Ac-PHSRN-NH2 (±SD).
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of equimolar scrambled LDV sequence peptide had no significant
effect on PHSRN-induced MMP-1. These results are consistent with
those obtained for normal human mammary and prostate epithelial
cells [3,4].
Inhibition of α5β1-Mediated Invasion and MMP-1
Secretion by PHSCN
The PHSCN peptide has been shown to have significant anti-
tumorigenic and antimetastatic activities in vivo [1,9–11]. Because an-
giogenesis is important for both tumorigenesis and metastasis, PHSCN
was evaluated for its ability to block α5β1-mediated invasion and
MMP-1 secretion by HMVEC. To evaluate the anti-invasive activity
of PHSCN, HMVECs were treated with Ac-PHSCN-NH2 at 1.7 μM
(1.0 μg/ml) and were placed on SU-ECM in the presence of 3.0 μg/
ml 120-kDa pFn CBD to elicit α5β1-mediated invasion. As shown in
Figure 3A, PHSCN prevented CBD-induced HMVEC invasion,
whereas an equal concentration of the scrambled PHSCN sequence
control had no effect. To assess the effects of PHSCN on FBS-induced
invasion, HMVECs were pretreated with 300 μg/ml P4C2 then
bound to 1.7 μM (1.0 μg/ml) PHSCN or HSPNC peptides and
placed on SU-ECM in 10% FBS. As shown in Figure 3B, expos-
ing the cells to PHSCN prevented P4C2-induced invasion, whereas
equal concentrations of HSPNC had no effect. The dose-response
relationship of PHSCN on PHSRN-induced invasion of SU-ECM
by HMVEC was determined, and the results are shown in Figure 3C :
HMVEC invasion was induced by 170 nM (100 ng/ml Ac-PHSRN-
NH2) and was inhibited with 17 nM to 1.7 μM (10 ng/ml to 1.0 μg/
ml) Ac-PHSCN-NH2. PHSRN-induced HMVEC invasion declined
log-linearly with increasing PHSCN peptide concentration and was
prevented at the highest concentrations. The scrambled PHSCN
sequence control, 1.7 μM (1.0 μg/ml) Ac-HSPNC-NH2, had no in-
hibitory effect. Analogous effects of PHSCN on PHSRN-induced
MMP-1 secretion by HMVEC were also observed in MMP-1 activity
assays, as shown in Figure 3D. The PHSRN peptide induced dose-
dependent MMP-1 secretion, and HSPNR had no effect. The pres-
ence of equimolar PHSCN peptide reduced PHSRN-induced MMP-1
secretion to background levels, whereas equimolar HSPNC peptide was
not inhibitory.
Regulation of Cell Surface α5β1 Integrin Levels in HMVEC
by PHSRN and PHSCN Peptides
Because higher levels of α5β1 receptors are observed on the surfaces
of endothelial cells in angiogenic sprouts [12–14], α5β1-mediated,
PHSRN-induced HMVEC invasion may involve the up-regulation
of surface α5β1, as well as MMP-1 secretion. Hence, the effects of
the PHSRN peptide on surface α5β1 and MMP-1 were assessed by
fluorescent antibody staining. Adherent HMVECs were treated for
2 hours with 0.5 μg/ml Ac-PHSRN-NH2 in FBS-containing me-
dium. Then, the PHSRN-treated HMVECs were fixed, and bound
to fluorescein-tagged anti-α5 integrin and rhodamine-tagged anti–
MMP-1 Ab. To visualize the locations of their nuclei, the cells were
also bound to 4′,6′-diamidino-2-phenylindole (DAPI). Similar experi-
ments were also performed with fluorescein-tagged P1D6 anti-α5β1
mAb. Immunofluorescence was quantitatively analyzed by confocal
microscopy, and the results are shown in Figure 4. Figure 4A shows
typical examples of anti-α5 Ab- and anti–MMP-1 Ab-stained and
DAPI-stained adherent HMVEC, after treatment with acetylated,
amidated PHSRN, HSPNR, PHSRN and LDV, PHSRN and scram-
bled LDV, PHSRN and PHSCN, or PHSRN and HSPNC peptides.
Figure 2. Inhibition of α5β1-mediated invasion by COMY4A2 anti–MMP-1, and regulation of MMP-1 secretion by FnR peptide ligands.
(A) Inhibition of PHSRN-induced invasion by COMY4A2 anti–MMP-1 mAb. X-axis, log micrograms of COMY4A2 mAb per milliliter; Y-axis,
mean percentages of invaded microvascular cells (±SD), relative to 0.1 μg/ml Ac-PHSRN-NH2, with no added mAb. All HMVEC induced
by 0.1 μg/ml Ac-PHSRN-NH2. Black circles, COMY4A2 anti–MMP-1; white circle, GE-213 anti–MMP-9; gray circle, CA-4001 anti–MMP-2;
black square, COMY4A2 isotype control. (B) Inhibition of P4C2-induced invasion by COMY4A2 anti–MMP-1. X-axis, log micrograms of
COMY4A2 mAb per milliliter; Y-axis, mean percentages of invaded microvascular cells (±SD), relative to HMVEC in 300 μg/ml P4C2 anti-
α4β1, without anti-MMP mAb. Black circles, increasing concentrations of COMY4A2 anti–MMP-1; black square, 300 μg/ml CA-4001 anti–
MMP-2; white circle, 300 μg/ml GE-213 anti–MMP-9. (C) Effects of PHSRN and LDV peptides on MMP-1 secretion. X-axis, treatments: a,
no added peptide; b, Ac-PHSRN-NH2 (5 μg/5 ml per 20,000 cells); c, Ac-LHGPEILDVPST-NH2 (12.5 μg/5 ml per 20,000 cells); d, equi-
molar Ac-PHSRN-NH2 and Ac-LHGPEILDVPST-NH2 (5 μg/5 ml per 20,000 cells and 12.5 μg/5 ml per 20,000 cells, respectively); e, equi-
molar Ac-PHSRN-NH2 and Ac-PGVLSEHPTLID-NH2 (5 μg/5 ml per 20,000 cells and 12.5 μg/5 ml per 20,000 cells, respectively). Y-axis,
mean relative MMP-1 concentrations (±SD). *P < .01.
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PHSRN peptide treatment caused a rapid increase in anti-α5 integrin
Ab immunostaining, as well as a corresponding increase in anti–
MMP-1 binding, whereas HSPNR peptide treatment had no effect,
thus confirming the sequence specificity of PHSRN-induced α5 and
MMP-1 up-regulation. PHSRN-induced α5 up-regulation was likely
to result from the binding of PHSRN by the α5β1 integrin because
inclusion of an equimolar amount of the α4β1 integrin fibronectin
receptor LDV peptide ligand prevented both α5β1 and MMP-1 up-
regulation, whereas inclusion of equimolar scrambled LDV sequence
peptide had no effect. PHSRN-induced α5 and MMP-1 up-regulation
could also be prevented by the inclusion of the transcription inhibitor,
actinomycin D, suggesting that the observed changes in cell surface
levels of α5β1 and MMP-1 may involve changes in gene expression.
Consistent with its ability to inhibit α5β1-mediated, PHSRN-induced
invasion, an equimolar concentration of the PHSCN peptide pre-
vented PHSRN-induced surface α5 integrin up-regulation, whereas
the HSPNC scrambled sequence control had no effect. Identical re-
sults were obtained for all of these assays using fluorescein-tagged
P1D6 anti-α5β1 mAb (not shown). Figure 4B shows the quantitation
of these effects on surface α5 and α5β1 levels (obtained with anti-α5
Ab and with P1D6 anti-α5β1 mAb) and MMP-1 levels (obtained with
anti–MMP-1 Ab). PHSRN treatment increased mean anti-α5 and
α5β1 fluorescence levels by three- to four-fold, respectively. PHSRN
treatment also increased mean anti–MMP-1 fluorescence levels by
four-fold. PHSRN induction of anti-α5, anti-α5β1, and anti–MMP-1
immunofluorescence was prevented by actinomycin D and by the
LDV and PHSCN peptides. Scrambled sequence controls for the
LDV and PHSCN peptides had no effect on PHSRN-induced up-
regulation. The ability of the PHSRN peptide to induce invasion by
surface α5β1 up-regulation and the invasion-inhibitory function of
α4β1 suggest that PHSRN-treated HMVEC should not exhibit in-
creased surface α4β1. This was tested by comparing immunofluorescent
staining of PHSRN- and HSPNR-treated HMVEC using the follow-
ing primary antibodies: P4C2 anti-α4β1 mAb, anti–MMP-1 Ab, P1D6
anti-α5β1 mAb, and anti-α5 Ab. As shown in Figure 4C , PHSRN treat-
ment caused a significant up-regulation of surface α5β1, as indicated by
Figure 3. Inhibition of α5β1-mediated invasion, and PHSRN-induced MMP-1 secretion by PHSCN. (A) Inhibition of CBD-induced HMVEC
invasion by PHSCN. X-axis, HMVEC treatment: 120 kDa, 3 μg/ml 120-kDa pFn CBD; 120 kDa + PHSCN, 3 μg/ml 120-kDa pFn CBD +
1 μg/ml Ac-PHSCN-NH2; 120 kDa + HSPNC, 3 μg/ml 120-kDa pFn CBD + 1 μg/ml Ac-HSPNC-NH2. Y-axis, mean percentages of invaded
cells (±SD). *P< .01. (B) Inhibition of P4C2 mAb-induced invasion by PHSCN. X-axis, HMVEC treatment: anti-α4β1, 300 μg/ml P4C2; anti-
α4β1 + PHSCN, 300 μg/ml P4C2 + 1.0 μg/ml Ac-PHSCN-NH2; anti-α4β1 + HSPNC, 300 μg/ml P4C2 + 1.0 μg/ml Ac-HSPNC-NH2. Y-axis,
mean percentages of invaded cells (±SD). *P < .01. (C) Inhibition of PHSRN-induced invasion by PHSCN. X-axis, log nanograms of
peptide concentrations per milliliter; Y-axis, mean percentages of invaded cells relative to 1.0 μg/ml Ac-PHSRN-NH2 (±SD). Black cir-
cles, Ac-PHSCN-NH2; white circle, Ac-HSPNC-NH2. All samples contained 1.0 μg/ml Ac-PHSRN-NH2. (D) Inhibition of PHSRN-induced
MMP-1 secretion by PHSCN. X-axis, peptide treatment: a, 1 μg of Ac-PHSRN-NH2/ml per 20,000 cells; b, 3 μg of Ac-PHSRN-NH2/ml per
20,000 cells; c, 10 μg of Ac-PHSRN-NH2/ml per 20,000 cells; d, 1 μg of Ac-HSPNR-NH2/ml per 20,000 cells; e, 1 μg of Ac-PHSCN-NH2/ml
per 20,000 cells; f, 1 μg of Ac-HSPNC-NH2/ml per 20,000 cells; g, Ac-PHSRN-NH2 and Ac-PHSCN-NH2, each 1 μg/ml per 20,000 cells; h,
Ac-PHSRN-NH2 and Ac-HSPNC-NH2, each 1 μg/ml per 20,000 cells. Y-axis, mean MMP-1 concentrations relative to untreated controls:
triplicate samples without added peptide (±SD).
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P1D6 mAb and anti-α5 Ab immunostaining, as well as MMP-1; but
failed to induce increased surface α4β1. These results were confirmed
by immunoblot analysis as shown in the inset to Figure 4C . Immuno-
blots of extracts from membranes of PHSRN-treated HMVEC exhib-
ited a 5.5-fold increase in CD 49e anti-α5 mAb immunoreactivity,
relative to untreated controls, whereas extracts from HSPNR-treated
HMVEC showed no increase. Also, whereas membrane-bound α5 in-
tegrin was increased by PHSRN treatment, the levels of β1 integrin
in P4C2 anti-α4 immunoprecipitates remained unchanged. These re-
sults are both qualitatively and quantitatively similar to those obtained
by immunofluorescence analysis (Figure 4B) and show that PHSRN
specifically induces the up-regulation of membrane-bound, invasion-
stimulatory α5β1 without affecting levels of the invasion-inhibitory
α4β1 fibronectin receptor.
Figure 4. Up-regulation of α5β1 and MMP-1 by PHSRN and inhibition by PHSCN. (A) HMVEC, stained with fluorescein-coupled anti-α5 Ab,
rhodamine-coupled anti–MMP-1 Ab, and DAPI. Peptide treatments and 5-μm bar are indicated. (B) Quantitation of fluorescence in
HMVEC stained with fluorescein-coupled P1D6 anti-α5β1 mAb or anti-α5 Ab and rhodamine-coupled anti–MMP-1 Ab. X-axis, peptide
treatments; Y-axis, mean fluorescence levels (±SD). PHSRN and HSPNR: 0.5 μg/ml; LDV and scrambled LDV: 1.5 μg/ml; PHSCN
and HSPNC: 0.5 μg/ml. Act. D, actinomycin D; gray bars, P1D6 mAb; black bars, anti-α5 Ab; white bars, anti–MMP-1 Ab. (C) Fluores-
cence quantitation in HMVEC stained with P4C2 anti-α4β1, anti–MMP-1 Ab, P1D6 anti-α5β1 mAb or anti-α5 Ab. X-axis, peptide treat-
ments; Y-axis, mean fluorescence (±SD). PHSRN and HSPNR as described above. White bars, P4C2 anti-α4β1 mAb; light gray bars,
anti–MMP-1 Ab; dark gray bars, P1D6 anti-α5β1 mAb; black bars, anti-α5 Ab. Inset: Effects of PHSRN or HSPNR on α5β1 and α4β1 levels
in HMVEC plasma membranes. Anti-α5 Ab immunoblot: mean (±SD) relative densities of α5 bands from membrane extracts of PHSRN-
treated HMVEC: 8.2 (±0.8); mean (±SD) relative densities of α5 bands from HSPNR-treated HMVEC: 1.5 (±0.5). P < .01. Anti-β1 im-
munoblots of anti-α4 immunoprecipitates from membrane extracts of PHSRN- or HSPNR-treated HMVEC: mean (±SD) relative density
of β1 band from PHSRN-treated HMVEC: 1.1 (±0.1); mean (±SD) relative density of β1 band from HSPNR-treated HMVEC: 1.1 (±0.0).
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Regulation of α5 Integrin mRNA Levels in HMVEC by
PHSRN, LDV, and PHSCN Peptides
Inhibition of PHSRN-induced α5 up-regulation by actinomycin
D suggested that PHSRN may stimulate transcription of the gene
encoding the α5 integrin subunit. This was tested by treating adher-
ent HMVEC with PHSRN or HSPNR peptides, and by ascertaining
the effects of equimolar concentrations of the LDV and PHSCN
peptides or their scrambled sequence controls, on PHSRN-induced
α5 mRNA levels by performing RT-PCR analysis. As shown in Fig-
ure 5, treatment of adherent HMVEC with PHSRN for 12 hours
significantly increased α5 mRNA levels, whereas treatment with
HSPNR had no effect. Although the fold increase in surface α5β1
in PHSRN-treated HMVEC, as determined by fluorescent antibody
staining and by Western blot analysis (Figure 4), may be somewhat
greater than the fold increase in α5 mRNA, it has been previously
reported that the quantitative correlation between mRNA and pro-
tein expression is often imperfect because of important posttranscrip-
tional regulatory mechanisms [39]. As shown in Figure 5, equimolar
LDV peptide prevented PHSRN-induced α5 mRNA induction, whereas
scrambled LDV peptide had no effect. On the basis of the known
ability of the α4β1/LDV interaction to inhibit PHSRN-induced in-
vasion [3,4], as well as Fn CBD-induced MMP-1 transcription [37],
these results suggest that the α5β1/PHSRN interaction stimulates
transcription of the α5 integrin subunit gene. The results shown in
Figure 5 also indicate that the presence of equimolar PHSCN pep-
tide prevented PHSRN-induced α5 mRNA induction in HMVEC,
whereas the HSPNC scrambled sequence control had no effect.
Inhibition of PHSRN-Induced α5β1 and MMP-1
Up-regulation and PHSRN-Induced Invasion by
α5 Integrin siRNA
The induction of α5 mRNA by PHSRN peptide treatment sug-
gested that transcription of the gene encoding the α5 integrin sub-
unit might be necessary for both surface α5β1 up-regulation and
α5β1-mediated invasion in HMVEC. To evaluate the requirement
for α5 mRNA in PHSRN-induced surface α5β1 up-regulation, ad-
herent HMVECs transfected with α5 or nonspecific control (NC)
siRNA were treated with PHSRN peptide. Treated cells were stained
with anti-α5β1 and MMP-1 primary and fluorescent secondary anti-
bodies and were analyzed by confocal microscopy. Mean fluorescence
levels are shown in Figure 6A with their first SDs. Integrin α5 siRNA
inhibited the expression of α5 subunit mRNA in adherent, fluores-
cent antibody–stained, PHSRN-treated HMVECs (images not shown).
Irrespective of which siRNA was expressed, surface α5β1 integrin and
cytoplasmic MMP-1 levels differed only slightly in untreated HMVEC.
However, PHSRN induction of both α5β1 and MMP-1 declined
Figure 5. Induction of α5 mRNA by the PHSRN/α5β1 interaction.
X-axis, peptide treatment: 1 μg/ml/20,000 cells PHSRN, HSPNR,
PHSCN, or HSPNC peptides; 2.5 μg/ml/20,000 cells LDV or scr.
LDV peptides: Y-axis, mean relative α5 mRNA levels (±SD). P values
for all starred comparisons: P < .01.
Figure 6. Inhibition of PHSRN-induced α5β1 and MMP-1 up-regulation, and PHSRN-induced invasion by α5 silencing. (A) Fluorescence
quantitation of HMVEC, expressing either α5 or nonspecific control (NC) siRNA. X-axis, treatments; black bars, α5 siRNA; gray bars, NC
siRNA; Y-axis, mean expression levels (±SD). (B) Effects of PHSRN peptide treatment on invasion by HMVEC expressing either α5 or NC
siRNA. X-axis, treatments; Y-axis, mean invasion percentages (±SD).
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significantly in α5 siRNA-expressing HMVEC, relative to those ex-
pressing NC siRNA. Consistent with these results, PHSRN-induced
invasion was prevented in HMVEC expressing α5 siRNA, whereas it
was unaffected by the expression of NC siRNA, as shown in Figure 6B.
Inhibition of PHSRN-Induced Angiogenesis in Matrigel
Plugs by Systemic PHSCN
PHSRN-induced, α5β1-mediated angiogenesis was assessed in nude
mice bearing Matrigel plugs [40,41]. Varying amounts of acetylated,
amidated PHSRN, ranging from 0.1 to 2.5 mg, were included in
Matrigel plugs, implanted subcutaneously. Plugs containing 2.5 mg
of the HSPNR control were also included, as were plugs containing
400 ng of bFGF, a known proangiogenic agent [40]. After 5 days, plugs
were removed and fixed; frozen sections were stained with Biebrich
scarlet acid fuchsin and were counterstained with aniline blue. Neovas-
cularization was quantitated by confocal microscopy. Each treatment
group consisted of four to five nude mice, each bearing two plugs. As
shown in Figure 7A, inclusion of PHSRN stimulated angiogenesis in
a dose-dependent fashion, whereas inclusion of 2.5 mg of HSPNR
had no effect. At the highest PHSRN dose, the mean numbers of
microvessels observed were indistinguishable from the numbers ob-
served in the bFGF-positive control.
Because the PHSCN peptide may bind purified α5β1 integrin and
has been reported to inhibit vascular endothelial growth factor– and
bFGF-induced angiogenesis in Matrigel plugs [42], the antiangiogenic
activity of systemic PHSCN was assessed in Matrigel plugs, each con-
taining 0.5 mg of PHSRN to induce α5β1-mediated angiogenesis,
as above. While mice bore the plugs, they received three intravenous
doses of PHSCN in NS; doses varied from 10 to 300 μg (0.5-15 mg/
kg), the optimal systemic dose range for this agent [1,42]. Mice bear-
ing plugs containing 0.5 mg of HSPNR were included as negative
controls for PHSRN-induced angiogenesis; these mice received in-
travenous NS only. Also, mice bearing plugs containing 0.5 mg of
PHSRN peptide were treated intravenously with 500 μg (25 mg/kg)
of HSPNC as negative controls for systemic PHSCN therapy. Mice
bearing plugs containing bFGF were also included, as above. After
5 days, all plugs were removed, fixed, sectioned, stained, and assayed
as above. Increasing doses of intravenous PHSCN peptide inhibited
PHSRN-induced angiogenesis in Matrigel plugs in a dose-dependent
fashion, as shown in Figure 7B. Also, no angiogenesis inhibition was
observed in HSPNC-treated mice. Figure 7C shows typical examples
of the sections analyzed in these experiments: Matrigel only, Matrigel
with 0.5 mg of PHSRN, and Matrigel with 0.5 mg of PHSRN, after
a total of three intravenous doses of PHSCN (15 mg/kg).
Figure 7. PHSCN inhibition of PHSRN peptide–induced angiogenesis in Matrigel plugs. (A) Angiogenesis induction by addition of
PHSRN. X-axis, additions to Matrigel: PHSRN, Ac-PHSRN-NH2; HSPNR, Ac-HSPNR-NH2; bFGF, 400 μg of bFGF. Y-axis, mean number
of microvessels per field (±SD). (B) Inhibition of PHSRN-induced angiogenesis by systemic PHSCN peptide treatment. X-axis, additions
to Matrigel (Ac-PHSRN-NH2, Ac-HSPNR-NH2, or bFGF) and systemic treatments: PHSCN, Ac-PHSCN-NH2; HSPNC, Ac-HSPNC-NH2.
Y-axis, mean number of microvessels per field (±SD), n = 30. (C) Examples of sectioned Matrigel plugs. Bars, 20 μm.
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Hemoglobin Content Reduction in Matrigel Plugs with
PHSRN Peptide or MATLyLu Cells
We verified that systemic PHSCN could reduce PHSRN-induced,
α5β1-mediated neovascularization in Matrigel plugs by quantitating
its effects on hemoglobin content. Angiogenesis was induced by in-
clusion of 2.5 mg of PHSRN per plug, followed by biweekly injec-
tions of 1.25 mg of PHSRN directly into each plug. Analogous
procedures were followed for the HSPNR control. After 16 days
and a total of seven intravenous injections of 15 mg/kg PHSCN
or HSPNC in NS (or of NS alone), the effects on PHSRN-induced
angiogenesis, as indicated by hemoglobin content, were evaluated
by Drabkin assay, as described [30]. As shown in Figure 8A, the
PHSRN-induced increase in hemoglobin content of Matrigel plugs
was completely prevented by systemic PHSCN, but unaffected by
HSPNC, given at an identical dosage schedule.
The antiangiogenic activity of systemic PHSCN was also assessed
in mice bearing Matrigel plugs, each implanted with 2 million
MATLyLu rat prostate cancer cells, a commonly used model of met-
astatic prostate cancer [43], to induce angiogenesis. As shown in
Figure 8B, MATLyLu cells increased the mean hemoglobin content
of the Matrigel plugs by approximately three-fold after 9 days, com-
pared with plugs containing Matrigel alone. Thrice weekly, 0.3-mg in-
travenous doses of PHSCN peptide prevented MATLyLu-induced
angiogenesis, as indicated by reduced hemoglobin content, whereas
treatment with HSPNC had no effect. These results are consistent
with both the effects of systemic PHSCN peptide on angiogenesis
in Matrigel plugs containing PHSRN (Figure 7B) and the antiangio-
genic effects of systemic PHSCN therapy in rats bearing MATLyLu
tumors [1].
Regulation of Cell Surface α5β1 Integrin Levels in Endothelial
Cells in Matrigel Plugs by PHSRN and PHSCN Peptides
Matrigel plugs containing various doses of the PHSRN peptide
were injected into the groins of female, nude mice. After 5 days,
the plugs were removed, sectioned, and stained with anti-α5 Ab,
anti-α5β1 P1D6 mAb, or anti–MMP-1 Ab, and with DAPI. Confocal
microscopy was used to quantitate immunofluorescence in the vas-
culature of immunostained, sectioned plugs, and the results are
shown in Figure 9. Figure 9A shows typical examples of sectioned
Matrigel plugs, containing various amounts of acetylated, amidated
PHSRN peptide, ranging from 0.1 to 2.5 mg per plug. These sections
were reacted with fluorescein-coupled anti-α5 and rhodamine-coupled
anti–MMP-1 Ab. Compared with plugs containing no PHSRN
peptide, the endothelial cells in the microvasculature of the PHSRN-
containing plugs exhibited higher levels of both anti-α5 and anti–
MMP-1 immunofluorescence, which were further increased with
higher PHSRN peptide doses. Identical results were obtained with
P1D6 anti-α5β1 mAb (not shown). Mean fluorescence levels observed
in 30 randomly chosen fields of five sections spanning 100 μm from
duplicate Matrigel plugs were quantitated for each PHSRN concentra-
tion and control. Mean immunofluorescence levels for P1D6 anti-α5β1
(gray bars), anti-α5 Ab (black bars), and anti–MMP-1 Ab (white bars)
are plotted with their first SDs. As shown in Figure 9B, mean surface
levels of anti-α5β1, anti-α5, and anti–MMP-1 antibodies increased
with PHSRN dose, in proportion to the increased vascularization
shown in Figure 7A. Figure 9C shows typical examples of sectioned
Matrigel plugs, containing 2.5 mg of PHSRN peptide, where the mice
received systemic doses of PHSCN peptide in NS, ranging from 10 to
300 μg. Some mice had PHSRN-containing plugs but received only
NS systemically. Sections were reacted with fluorescein-coupled anti-α5
and rhodamine-coupled anti–MMP-1 Ab. Compared with plugs con-
taining 2.5 mg of PHSRN peptide, in mice receiving systemic NS
only, the endothelial cells in the microvasculature of the PHSRN-
containing plugs from mice dosed with PHSCN peptide systemically
exhibited lower levels of both anti-α5 and anti–MMP-1 immuno-
fluorescence and immunofluorescence decreased with higher systemic
PHSCN peptide doses. Very similar results were obtained with P1D6
anti-α5β1 mAb (not shown). Figure 9D shows the quantitation of the
Figure 8. Inhibition of PHSRN or MATLyLu-induced angiogenesis in Matrigel plugs by systemic PHSCN: Drabkin assays. (A) Inhibition of
PHSRN-induced angiogenesis in Matrigel plugs by systemic PHSCN. X-axis, additions to Matrigel and systemic treatments: HSPNR,
0.1 mg of Ac-HSPNR-NH2 added to Matrigel plugs; PHSRN, 0.1 mg of Ac-PHSRN-NH2 added to Matrigel plugs; PHSRN + PHSCN,
0.1 mg of Ac-PHSRN-NH2 added to Matrigel plugs, with thrice weekly dosages of Ac-PHSCN-NH2 at 15 mg/kg; PHSRN + HSPNC, 0.1 mg
of Ac-PHSRN-NH2 added to Matrigel plugs, with thrice weekly dosages of Ac-HSPNC-NH2 at 15 mg/kg. Y-axis, hemoglobin (Hb) content:
mean absorbance at 540 nm (A540 nm, ±SD). (B) Inhibition of MATLyLu-induced angiogenesis by systemic PHSCN. X-axis, additions to
Matrigel and systemic treatments:—,Matrigel only;MLL,Matrigel +MATLyLu cells; PHSCN, 0.3mg (15mg/kg) of Ac-PHSCN-NH2; HSPNC,
0.3 mg (15 mg/kg) of Ac-HSPNC-NH2. Y-axis, hemoglobin (Hb) content: mean absorbance at 540 nm (A540 nm, ±SD). *P < .01.
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mean fluorescence levels observed in 30 randomly chosen fields of five
sections spanning 100 μm from duplicate Matrigel plugs for each sys-
temic PHSCN concentration and control. Mean surface levels of fluo-
rescent anti-α5β1 mAb and anti-α5 and anti–MMP-1 Ab decreased
with the PHSCN dose, in proportion to the decreased vascularization
shown in Figure 7B.
Discussion
The α5β1 FnR plays a key role in mediating invasion by endothelial
cells in the early stages of angiogenesis during embryogenesis, or-
ganogenesis, and wound healing [14,15,44–47]. Whereas α5β1 is ex-
pressed at low levels in quiescent endothelium, surface levels of α5β1
are greatly upregulated in activated endothelial cells and in tumor vas-
culature [12,16,45]. Results presented here suggest that the PHSRN
peptide interacts with the α5β1 receptors of HMVEC to induce in-
vasion by upregulating surface α5β1 expression through increased ex-
pression of the α5 integrin gene. Substantial PHSRN-induced α5β1
up-regulation was observed in vitro on the surfaces of adherent
HMVEC and in vivo on the endothelial cells of the microvasculature
in PHSRN-treated Matrigel plugs.
Our results also show that the PHSRN peptide ligand of α5β1 FnR
induces HMVEC invasion, similar to observations for normal human
epithelial cells and neonatal fibroblasts [1–3]. PHSRN-induced, α5β1-
mediated invasion is inhibited by the α4β1/Fn LDV interaction as
observed for mammary epithelial cells [3]. Moreover, whereas block-
ing anti-α5β1 mAb prevents PHSRN-induced invasion, blocking
anti-α4β1 mAb induces dose-dependent invasion and α4β1-induced
invasion specifically requires pFn. Exposure to PHSRN also stimulates
MMP-1 secretion, as it does for several types of epithelial cells and fibro-
blasts; moreover, equimolar LDV blocks PHSRN-induced MMP-1.
These results are consistent with the finding that the α5β1/Fn CBD
interaction induces MMP-1 secretion, which is blocked by the α4β1/
LDV interaction in intact Fn [37]. α5β1-Mediated invasion specifi-
cally requires MMP-1 because both PHSRN- and anti–α4β1-induced
Figure 9. PHSCN inhibition of PHSRN-induced α5β1 and MMP-1 up-regulation in Matrigel plugs. (A) Examples of sectioned PHSRN-
treated Matrigel plugs stained with fluorescein-coupled anti-α5 antiserum and rhodamine-coupled anti–MMP-1 antiserum. PHSRN doses
are as shown. Bar, 20 μm. (B) Quantitation of fluorescence levels in sectioned PHSRN-treated Matrigel plugs stained with fluorescein-
coupled anti-α5 antiserum and rhodamine-coupled anti–MMP-1 antiserum. X-axis, peptide treatments; Y-axis, mean fluorescence levels
(±SD). PHSRN, Ac-PHSRN-NH2; gray bars, P1D6 mAb; black bars, anti-α5 Ab; white bars, anti–MMP-1 Ab. (C) Examples of sectioned
PHSRN-treated Matrigel plugs from mice receiving systemic PHSCN therapy at the doses shown, stained with fluorescein-coupled anti-
α5 antiserum and rhodamine-coupled anti–MMP-1 antiserum. Amount of PHSRN in all Matrigel plugs: 2.5 mg. Bar, 20 μm. Systemic
PHSCN doses are as shown: 0.03, 0.1, and 0.3 mg. (D) Inhibition of PHSRN-induced α5β1 up-regulation by systemic PHSCN peptide
treatment. X-axis, additions to Matrigel: PHSRN, Ac-PHSRN-NH2; PHSCN, Ac-PHSCN-NH2. Y-axis, mean number of microvessels per
field (±SD). Gray bars, P1D6 mAb; black bars, anti-α5 Ab; white bars, anti–MMP-1 Ab.
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HMVEC invasion are prevented dose dependently by increasing con-
centrations of blocking anti–MMP-1 mAb. MMP-1 is one of four
MMPs that degrades native interstitial collagen, including types I, II,
III, and other fibrillar collagens [48]. MMP-1 is required for angiogene-
sis in vitro [38]. It functions in endothelial cell migration through the
extracellular matrix during the earliest stages of angiogenesis, perhaps by
removing barriers at the leading edges of angiogenic sprouts [49,50].
Although the induction of α5β1-meditated, MMP-1–dependent in-
vasiveness in PHSRN-treated microvascular endothelial cells may have
been expected given the role of the PHSRN/α5β1 interaction in in-
vasion induction by normal human fibroblasts and epithelial cells
[1–4], α5β1 up-regulation on the surfaces of PHSRN-treated HMVEC
in vitro and in PHSRN-treated Matrigel plugs in vivo, the rapid in-
duction of α5 mRNA by PHSRN treatment, and the necessity of α5
gene transcription for PHSRN-stimulated invasion were unanticipated
consequences of the PHSRN/α5β1 interaction. Exposure to angiogenic
growth factors, such as bFGF and transforming growth factor β1, is
known to stimulate increased α5 mRNA without inducing β1 in micro-
vascular endothelial cells, for example [12]; however, specific induction
of α5 mRNA as a direct result of the interaction of α5β1 with its natural
ligand, the PHSRN sequence, has not been reported previously. Our
results suggest that this interaction may also play a significant role in
the up-regulation of α5β1 receptors observed on activated endothelial
cells and in tumor vasculature [12,16,45] and that a feed-forward
α5β1 up-regulation in the absence of a corresponding increase in surface
α4β1 receptors may be an important mechanism for inducing endothe-
lial cell invasion to stimulate angiogenesis. The ability of inflammatory
pathways to upregulate their own ligands or receptors, thereby resulting
in feed-forward signals, has been proposed to be a key feature of inflam-
mation and tumor development, for example [51,52].
The results presented here also show that the PHSCN peptide
(ATN-161), an invasion inhibitor that prevented metastatic disease
progression and recurrence for prolonged periods in preclinical models
and in phase 1 clinical trial [1,8–11], blocks α5β1-mediated HMVEC
invasion, whether induced by the Fn CBD, blocking anti-α4β1 mAb,
or PHSRN peptide. Furthermore, we also report that PHSCN pre-
vents PHSRN-induced α5β1 up-regulation and α5 mRNA induction
in vitro in adherent HMVEC, as expected from its ability to interact
with α5β1 to inhibit invasion induction [1,2,9–11]. Systemic PHSCN
therapy was also found to inhibit α5β1-mediated, PHSRN-induced
neovascularization in Matrigel plugs. Results of microvessel scoring
and Drabkin hemoglobin assays show that PHSCN therapy sig-
nificantly reduces angiogenesis in Matrigel plugs, whether induced
by inclusion of PHSRN peptide to directly stimulate endothelial
α5β1 receptors or metastatic MATLyLu cells [43]. We also observed
that systemic PHSCN therapy downregulates surface levels of α5β1
integrin and MMP-1 on the endothelial cells of the microvascula-
ture in PHSRN-treated Matrigel plugs, suggesting that PHSCN may
block angiogenesis in vivo in part through its inhibitory effects on
α5β1 up-regulation.
Because tumor vascularization promotes both tumorigenesis and
metastasis, inhibition of α5β1 may thus form the basis of potent,
nontoxic antitumorigenic and antimetastatic therapies [1,6,8–11].
Angiogenesis leading to excess neovascularization contributes to sev-
eral diseases, including macular degeneration [14], atherosclerosis
[53], and asthma [54], as well as tumor growth and metastasis. Thus,
the importance of α5β1 integrin in angiogenesis suggests that tar-
geted, nontoxic inhibitors of activated α5β1 may also be useful in
treating these diseases.
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